Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGRIT adjuvant recMAGE-A3 + AS15 in resected MAGE-A3-positive NSCLC
2007-001283-73Phase 3Terminated
- Sponsor
- GSK
- Start
- Apr 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing recMAGE-A3 + AS15 with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Apr 2007; status: terminated.
02
Drugs
recMAGE-A3 + AS15
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-001283-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001283-73.